TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05977959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring Program
Description: Schools in this group will participate in meetings and discussion boards and receive newsletters to help with program implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring Program
Description: Schools in this group will participate in meetings and discussion boards and receive newsletters to help with program implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring Program
Description: Schools in this group will participate in meetings and discussion boards and receive newsletters to help with program implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring Program
Description: Schools in this group will participate in meetings and discussion boards and receive newsletters to help with program implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Resources
Description: Schools in this group will receive extra resources such as program incentives to aid in program implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Resources
Description: Schools in this group will receive extra resources such as program incentives to aid in program implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Resources
Description: Schools in this group will receive extra resources such as program incentives to aid in program implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Resources
Description: Schools in this group will receive extra resources such as program incentives to aid in program implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Engagement
Description: Schools in this group will participate in program contests to aid program implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Engagement
Description: Schools in this group will participate in program contests to aid program implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Engagement
Description: Schools in this group will participate in program contests to aid program implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Engagement
Description: Schools in this group will participate in program contests to aid program implementation.
Study: NCT04534153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine Hydrochloride without sodium lauryl sulfate
Description: without sodium lauryl sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine Hydrochloride with sodium lauryl sulfate
Description: with sodium lauryl sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine Hydrochloride with sodium lauryl sulfate
Description: with sodium lauryl sulfate
Study: NCT05396768

Intervention type: OTHER
Intervention: Assessment using the ACTION-tool.
Description: Participants will be assessed using the ACTION-tool while they are performing a CTI on a porcine rib model and Thiel embalmed human cadavers.

Intervention type: OTHER
Intervention: Assessment using the ACTION-tool.
Description: Participants will be assessed using the ACTION-tool while they are performing a CTI on a porcine rib model and Thiel embalmed human cadavers.
Study: NCT06299800

Intervention type: OTHER
Intervention: phenotyping of patients followed at a third-level diabetes centre with cancer
Description: Collection of the following data for each patient enrolled, where possible:~* Gender and age;~* Smoking habits and alcohol consumption (units per day);~* Weight and body mass index (BMI) at first (T0) and last visit (T1);~* Given by the diagnosis of type 2 diabetes mellitus;~* Treatment of type 2 diabetes at T0 and T1;~* Levels of glycated hemoglobin (hba1c) at T0 and T1, mean hba1c and mean fasting blood sugar;~* Creatinine clearance at T0 and T1;~* Liver enzymes at T0 and T1: alanine aminotransferase (ALT) and aspartate aminotransferase (AST);~* T0 and T1 lipid profile: low density lipoproteins (LDL-c) and triglycerides (TG);~* Complications of type 2 diabetes;~* Treatment of cancer;~* Family history of cancer.
Study: NCT01533532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH-2109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH-2109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH-2109

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04753866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Facial scanner
Description: The Bellus3D facial scanner will be used to scan the patient before and after implant rehabilitation in order to produce .obj files that allow 3D comparisons and to obtain discrepancy values regarding lip support.
Study: NCT05986110

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A training intervention on clinical ultrasound
Description: To train 20 primary care family doctors in clinical ultrasound so that they have greater power of resolution and allow them to limit the diagnostic and surgical times on the waiting lists of their patients.
Study: NCT05654038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 UCAR-NK cells
Description: The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set three different dose levels of UCAR-NK cells:Dose level one: 5-10×10\^6/kg; Dose level two:1-2×10\^7/kg; Dose level three:2-5×10\^7/kg.
Study: NCT05209919

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography
Description: All patients undergo physical examination, ECG, Transthoracic Echocardiography, six minutes walking test and blood sample (natruretic peptides, renal and liver function)

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography
Description: All patients undergo physical examination, ECG, Transthoracic Echocardiography, six minutes walking test and blood sample (natruretic peptides, renal and liver function)

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography
Description: All patients undergo physical examination, ECG, Transthoracic Echocardiography, six minutes walking test and blood sample (natruretic peptides, renal and liver function)

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography
Description: All patients undergo physical examination, ECG, Transthoracic Echocardiography, six minutes walking test and blood sample (natruretic peptides, renal and liver function)
Study: NCT05012267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16-hour PP
Description: PP according to previous study
Study: NCT04577508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Remediation
Description: Functional Remediation is a manualized, group-based psychosocial intervention built on a neurocognitive-behavioural approach, involving modeling techniques, role-playing tasks, self-instruction, positive reinforcement and metacognitive cues (Vieta E et al, Cambridge University Press, 2014). It consists of 21 90-min weekly sessions, in which a trained therapist and co-therapist work with 10-12 patients: the first 3 sessions are dedicated to psychoeducation on neurocognitive deficits; then 13 sessions of neurocognitive training sequentially target attention, memory and executive functions domains, comprising exercises carried out individually, in pairs or in small groups; the last 5 sessions focus on skills training (communication, interpersonal relationships, autonomy, stress management). Content of the sessions involves ecological tasks adapted to real-world situations, and to-be-performed in two contexts (clinical and daily). Homework is assigned, collected and discussed each time.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Standard care for bipolar disorders according to good clinical practice, including drug therapy and individual case management.
Study: NCT06550778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based emotional regulation intervention
Description: The intervention was conducted once a week for 6 weeks, with each session lasting 90-120 minutes, including a 30-minute parenting course each week. The intervention program was divided into 6 themes, including Entering mindfulness, feeling the connection between emotions and the body, Dealing with negative emotions, Moderate emotional expression, Mindfulness to relieve anxiety, Learning to be grateful and Embrace future life. The intervention content integrates mindfulness training, parental mindful parenting exercises and emotion regulation skills. For details, refer to Greenland's Mindfulness Games, Bögels' Mindful Parenting Manual, mindful breathing and meditation in MBSR and MBCT, as well as emotion regulation skills. The intervention location was the activity room of the child and adolescent psychology unit of the hospital.
Study: NCT06374303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NE + Meal Delivery (NE+MD) intervention
Description: NE + Meal Delivery (NE+MD) participants received the same educational platform plus weekly meal deliveries using a commercial service that delivers premade, refrigerated meals directly to the participant's home.
Study: NCT05639036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Image Guided External Ventricular Drain Placement Using the NAV3 System
Description: Nav3 image guidance system used to assist with external ventricular drain placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Hand External Ventricular Drain Placement
Description: External ventricular drain will be placed with the standard free-hand technique
Study: NCT05485753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-038
Description: Administration by intravenous infusion
Study: NCT05553834

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Alirocumab and Cemiplimab
Description: Combination of PCSK9 inhibitor Alirocumab 150mg SC q2weeks and PD-I inhibitor Cemiplimab 350mg IV q3 weeks
Study: NCT06050681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: Participants will be asked to complete 21 mindfulness sessions within the Calm app on their own time and at a location of their choosing. They will be instructed to complete the '7 Days of Calm' program within the first two weeks of the intervention, the '7 Days of Managing Stress' program during weeks 3 \& 4 of the intervention, and the 'Letting Go of Anxiety' program during the final two weeks of the intervention. The sessions have a mean run time of 11.76 minutes. Each 7-day program will be completed within a 2-week period, which equates to about one session every other day, but can be completed at any interval within those 2 weeks. All 21 sessions will be completed within a 6-week period.
Study: NCT06284161

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Quadriceps Combined Test
Description: The recording of the motor response on the quadriceps is done using self-adhesive surface electrodes on the motor point of the vastus medialis muscles (active electrodes) and on the patella (reference electrode), using a classic electromyography device that allows calculations and measurements of amplitude, duration and speed.
Study: NCT05399797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational training
Description: Pharmacists in the intervention group will given detailed online educational training on how to recognize and manage acute uncomplicated urinary tract infections in adults.
Study: NCT06206187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated detection of the intracardiac thrombus through deep learning
Description: A deep learning model will identify the intracardiac thrombus. The AI model will produce an assessment of intracardiac thrombus using video based features.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrophysiologist judgment of the intracardiac thrombus
Description: Cardiac electrophysiologists use their own experience to determine whether there is intracardiac thrombus
Study: NCT04134039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyurethane (PU) condom
Description: A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyurethane (PU) condom
Description: A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natural Rubber Latex (NRL) condom
Description: A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natural Rubber Latex (NRL) condom
Description: A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
Study: NCT06180057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid
Description: Two capsules were administered orally
Study: NCT04351958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Augmented Reality (No Time Wasted)
Description: No Time Wasted will be an innovative, immersive intervention using novel technology that will captivate the target audience with narrative and gaming elements to scaffold the educational message.
Study: NCT05440916

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiotherapy: 5 x 4Gy
Description: Palliative irradiation of 2 to 5 sites (metastatic sites or/and primary lung tumour) in one week before systemic therapy. Systemic therapy should be given as soon as possible after irradiation.

Intervention type: DRUG
Group type: OTHER
Intervention: chemotherapy + immune checkpoint inhibitors
Description: Systemic therapy according to national/European recommendations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy + immune checkpoint inhibitors
Description: Systemic therapy according to national/European recommendations.
Study: NCT06180057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chenodeoxycholic acid leadiant
Description: Two capsules were administered orally
Study: NCT06032637

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pfannenstiel incision
Description: Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision halfway between the umbilicus and xiphoid process, extending laterally to the semilunar lines. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually using blunt dissection. The peritoneum will be incised transversely and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
Study: NCT04900571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 MG
Description: Comparison of alleviating post-operative pain between nitrofurantoin and calcium hydroxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 MG
Description: Comparison of alleviating post-operative pain between nitrofurantoin and calcium hydroxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 MG
Description: Comparison of alleviating post-operative pain between nitrofurantoin and calcium hydroxide
Study: NCT06032637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supra-umbilical transverse incision
Description: Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision 3-4cm above the umbilicus, extending laterally to the semilunar lines, without panniculus retraction. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. The rectus sheath will be incised transversely using electrocautery for hemostasis, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually along the midline using blunt dissection. The peritoneum will be transversely incised and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
Study: NCT05414994

Intervention type: OTHER
Intervention: Eye swab
Description: This is a simple swab under the eyelids of both eyes

Intervention type: OTHER
Intervention: Eye swab
Description: This is a simple swab under the eyelids of both eyes

Intervention type: OTHER
Intervention: Eye swab
Description: This is a simple swab under the eyelids of both eyes

Intervention type: OTHER
Intervention: Eye swab
Description: This is a simple swab under the eyelids of both eyes

Intervention type: OTHER
Intervention: Eye swab
Description: This is a simple swab under the eyelids of both eyes

Intervention type: OTHER
Intervention: Eye swab
Description: This is a simple swab under the eyelids of both eyes
Study: NCT06236555

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 8-iso Prostaglandin F2α and Adenosine Deaminase
Description: We took gingival crevicular fluid samples from patients who applied to our clinic and evaluated the -iso Prostaglandin F2α and Adenosine Deaminase levels in the samples.
Study: NCT05026762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Following the collection of the baseline data, the study participant will be assigned to a volunteer(medical student) to begin the social phone calls. The first phone call will be scheduled to occur within one week of the consent and baseline assessments. A minimum of one social phone call will occur each week for 6-weeks. Each phone call is expected to last up to 1 hour.The calls will be unstructured and designed simply to engage in conversation with the participant. The length of the phone calls, days and times will be recorded by the volunteer along with a short journal entry describing the conversation topics and any information that stood out to the volunteer.At the end of the 6-weeks phone calls, a group session will be held with the volunteers to engage in a debriefing and narrative medicine session.
Study: NCT06426420

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FTIR spectroscopy analysis
Description: ATR-FTIR Spectroscopy analysis combined with machine learning algorithms.
Study: NCT06147271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2i
Description: A randomized clinical trial of superiority with active control (2 arms), with central randomization to evaluate the efficacy and safety of adding dapagliflozin or empagliflozin 10 mg once daily to post-TxC routine compared with no intervention for 6-8 months.
Study: NCT05604898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
Description: 608 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
Description: 608 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
Description: 608 will be administered subcutaneously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo to maintain the blinding of the Investigational Medicinal Products.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo to maintain the blinding of the Investigational Medicinal Products.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo to maintain the blinding of the Investigational Medicinal Products.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
Description: 608 will be provided at pre-specified time intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
Description: 608 will be provided at pre-specified time intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
Description: 608 will be provided at pre-specified time intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
Study: NCT02896348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynPhNe platform
Description: SynPhNe is a non-invasive device. It consists of a piece worn around the forearm, a head component and it communicates wirelessly with the computer to provide feedback while performing motor tasks with the hemiparetic hand. The head cap records brain activity and gives feedback to help relaxing while exercising. The arm and the head component communicate wirelessly with the computer via Bluetooth. The head component reads brain signals while the arm gear senses your muscle signals when performing the exercises. The computer software adopts the appropriate difficulty level, speed and duration of the exercise depending on brain and muscle status to minimize fatigue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Exercise program established with a therapist (8 sessions under therapist direct supervision and 10 sessions at home). Low functioning subjects will be given more proximal joint-muscle exercises and activities while higher functioning subjects will have a greater component of distal tasks and activities. The therapist will review the exercises therapy plan with the subject and re-adjust it.